Categories: News

THE ADECCO GROUP Q4 & FULL YEAR 2025 RESULTS

Strong share gains and solid growth; operating leverage and cashflow drive deleveraging

- Advertisement -

ZURICH, Feb. 25, 2026 /PRNewswire/ — AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange

- Advertisement -

Q4 HIGHLIGHTS

- Advertisement -
  • Further market share gains, Group +395 bps and Adecco +240 bps
  • Group revenues further sequentially improved at +3.9% yoy, strongest quarter of the year
  • By GBU, Adecco revenues +4.9% yoy; led by Americas +21% yoy, APAC+7% yoy; Akkodis -1% yoy; LHH +2% yoy
  • Healthy 19.1% gross margin, stable yoy organic, reflecting solutions and client mix, firm pricing
  • 3.8% EBITA margin excl. one-offs, +60 bps yoy, reflecting strong operating leverage, with productivity +11% yoy, firm progress with Akkodis Germany turnaround. Drop-down ratio >80%
  • Operating income €186 million, +34% yoy; Net income €88 million, +31% yoy
  • Basic EPS €0.52; Adjusted EPS €0.76

FULL-YEAR HIGHLIGHTS

- Advertisement -
  • Strong market share gains, Group +245 basis points
  • Revenues +1.3% yoy. By GBU, Adecco +2.5% yoy; Akkodis -4% yoy; LHH flat yoy
  • Healthy 19.2% gross margin, -20 bps yoy, reflecting mix effects, firm pricing
  • 3.0% EBITA margin excl. one-offs, in line with management’s commitment
  • Operating income €572 million, +8% yoy; Net income €295 million, +2% yoy
  • Basic EPS €1.76; Adjusted EPS €2.37
  • Strong cash generation: operating cash flow +€613 million; free cash flow +€483 million; 102% conversion ratio
  • Improving financial structure: end-25 net debt/EBITDA ratio 2.4x, -0.2x yoy and -0.6x qoq; net debt €186 million lower yoy; targeting ≤ 1.5x net debt/EBITDA ratio by end-27
  • Proposed DPS of CHF 1.00, cash dividend with option to receive as shares

Denis Machuel, Adecco Group CEO, commented:

- Advertisement -

“We had a strong finish to the year with ongoing positive momentum and a third consecutive quarter of growth, achieving a 3.8% margin in Q4. Rigorous execution through 2025 delivered 245 basis points of market share gains, strong operating leverage and cashflow, driving an improvement in leverage.

- Advertisement -

“Adecco grew 4.9 percent in Q4, consistently gaining market share across regions. Akkodis saw further sequential improvement including firm progress in its German turnaround. LHH continued to lead strongly in career transition, grew Ezra significantly, and achieved highly profitable growth.

- Advertisement -

“The Adecco Group is strongly positioned to help our 100,000 plus clients to manage and upskill their workforces with agility – keeping people firmly at the heart. We will continue to pioneer and scale human-centric AI across talent and technology offerings. I look forward to building on this solid performance in 2026.”

- Advertisement -

Full Press Release

- Advertisement -

Webcast Details | Investors & Analysts

- Advertisement -

For further information, please contact:

- Advertisement -

Investor Relations
investor.relations@adeccogroup.com
+41 (0)44 878 88 88

- Advertisement -

Press Office
media@adeccogroup.com 
+41 (0) 79 876 09 21

- Advertisement -

Logo : https://mma.prnewswire.com/media/2919458/The_Adecco_Group_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/the-adecco-group-q4–full-year-2025-results-302696221.html

- Advertisement -

Recent Posts

China takes the lead in all Industry 4.0 technologies, ahead of U.S. and Europe

MHP and LMU Munich publish eighth edition of the Industry 4.0 Barometer China takes the…

5 hours ago

Craft,Confidence,andCreativity:WomenMakersandthePowerBehindtheToAutoCommunity

Shenzhen, March 17, 2026 (GLOBE NEWSWIRE) -- On March 8, International Women’s Day, the ToAuto…

5 hours ago

Lantronix to Showcase Intelligent PoE Infrastructure and Edge AI Solutions for Autonomous Systems at ISC West 2026

IRVINE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Lantronix Inc. (Nasdaq: LTRX), a global provider…

5 hours ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026 22:46 ET  | Source: SAB Biotherapeutics, Inc. MIAMI, March 17, 2026 (GLOBE…

9 hours ago

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

March 17, 2026 22:46 ET  | Source: CytomX Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., March…

9 hours ago

Blood Sugar Harmony Liquid Drops Ingredients Disclosed: Complete Details Revealed

Tallmadge, OH, March 17, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This content is for informational purposes…

9 hours ago